Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?

Gynecologic oncology - 1 Jul 2023

Witjes Vera M, Ligtenberg Marjolijn J L, Vos Janet R, Braspenning Jozé C C, Ausems Margreet G E M, Mourits Marian J E, de Hullu Joanne A, Adang Eddy M M, Hoogerbrugge Nicoline

Abstract excerpt

OBJECTIVE: Genetic testing in epithelial ovarian cancer (OC) is essential to identify a hereditary cause like a germline BRCA1/2 pathogenic variant (PV). An efficient strategy for genetic testing in OC is highly desired. We evaluated costs and effects of two strategies; (i) Tumor-First strategy, using a tumor DNA test as prescreen to germline testing, and (ii) Germline-First strategy, referring all patients to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Carcinoma, Ovarian Epithelial

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 37182432
DOI: 10.1016/j.ygyno.2023.04.029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?PMID 37182432Read ↗

Opportunities to improve detection of genetic predisposition for ovarian cancer applying the Tumor-First workflow.Semantic proximity Read ↗

Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.Semantic proximity Read ↗

[Genetic testing in epithelial ovarian cancer: implementation of the 'Tumor-First' workflow].Semantic proximity Read ↗

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Tumor Testing for BRCA Pathogenic Variants in Epithelial Ovarian Cancer.Semantic proximity Read ↗

Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.Semantic proximity Read ↗

The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants.Semantic proximity Read ↗

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionSemantic proximity Read ↗

BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients.Semantic proximity Read ↗

A review of the cost-effectiveness of genetic testing for germline variants in familial cancerSemantic proximity Read ↗

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.Semantic proximity Read ↗

BRCA Testing in Asian Patients with Ovarian Cancer: Standard Clinical Practice or Mutation Prediction Model?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.